95410-7
SARS-CoV-2 (COVID-19) neutralizing antibody [Titer] in Serum by pVNT
Active
Term Description
Quantitative titer results for SARS Coronavirus 2 (SARS-CoV-2) virus neutralizing antibodies in serum by pVNT (pseudovirus neutralization test). Neutralizing antibody testing is performed to determine whether the antibodies produced after SARS-CoV-2 infection or in response to a vaccination are able to neutralize the virus and prevent infection or re-infection. Different methods can be used to determine the presence of neutralizing antibodies, including VNT (virus neutralization test) and pVNT, which are represented in LOINC as the Method "Neutralization" and "pVNT", respectively. The pVNT method for SARS-CoV-2 neutralizing antibody testing uses recombinant pseudoviruses that incorporate the S protein from SARS-CoV-2, whereas VNT uses SARS-CoV-2 virus from a clinical isolate or recombinant SARS-CoV-2 expressing reporter proteins.
Source: Regenstrief LOINC
Part Descriptions
LP207365-0 Ab.Neut
Neutralizing antibodies are antibodies that interfere with the interaction between the virus and its host cell receptor, therefore preventing infectivity. Neutralizing antibodies can be detected using a traditional VNT or other methods such as pseudovirus VNT and surrogate VNT. VNT and pseudovirus VNT use live virus (the actual virus or a recombinant virus that incorporates the viral antigen of interest, respectively) and cell culture to assess the virus-host interaction and whether neutralizing antibodies are present that block that interaction. Surrogate VNT (sVNT) does not use live virus but rather uses purified viral antigen and host cell receptor protein to mimic the same interaction. The sVNT method is currently (2021) represented in LOINC as IA, because it is an immunoassay-based method.
Source: Regenstrief LOINC
LP417540-4 SARS coronavirus 2
The 2019 Novel Coronavirus (2019-nCoV) is a coronavirus first identified as the cause of a respiratory illness outbreak in Wuhan, China. Initially, the outbreak was linked to a large seafood and animal market and thought to only be spread by animal to person contact. Within a short time, a growing number of patients who had not been exposed to animal markets were diagnosed with the infection, indicating person-to-person transmission. As of January 2020, infections with 2019-nCoV had been reported internationally due to confirmed cases in travelers from Wuhan. Overall, clinical symptoms appear milder than SARS Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome (MERS) Coronavirus (MERS-CoV) infections as do the fatality rate and transmissibility. PMID: 31953166 Reported illnesses range from minor or no respiratory symptoms to severe acute respiratory illness and death.
The full genome of the 2019-nCoV was first posted by Chinese health authorities in GenBank, the NIH genetic sequence database, and in the Global Initiative on Sharing All Influenza Data (GISAI) portal. This facilitated detection of the virus globally with subsequent sequences being nearly identical, suggesting a single, recent emergence from a virus related to bat coronaviruses and the SARS coronavirus.
Source: LOINC
LP419175-7 pVNT
The pseudovirus neutralization test (pVNT) is similar to the conventional VNT; both are laboratory methods that are used primarily for identifying whether neutralizing antibodies for the virus of interest are present in the patient sample. The VNT involves incubating patient serum with the virus of interest, and then inoculating onto cell culture. If neutralizing antibodies are present and the virus is neutralized, the cells will not be infected. If neutralizing antibodies are not present, the virus will infect the cells in the cell culture. In the pVNT, a recombinant virus that incorporates the viral antigen of interest is used rather than the virus of interest itself. PMID: 32170698
Source: Regenstrief LOINC
Reference Information
Type | Source | Reference |
---|---|---|
Webcontent | Lab Tests Online®Copyright Copyright © 2021 Lab Tests Online. All rights reserved. | Coronavirus (COVID-19) Testing |
Fully-Specified Name
- Component
- SARS coronavirus 2 Ab.neut
- Property
- Titr
- Time
- Pt
- System
- Ser
- Scale
- SemiQn
- Method
- pVNT
Additional Names
- Short Name
- SARS-CoV-2 NAb Titr Ser pVNT
- Display Name
- SARS-CoV-2 (COVID-19) neut ab pVNT (S) [Titer]
- Consumer Name Alpha Get Info
- SARS-CoV-2 (COVID-19) neutralizing antibody, Blood
Ask at Order Entry
81959-9 Public health laboratory ask at order entry panel
This panel contains a convenience grouping of terms for questions commonly asked when an order is placed in a public health laboratory.
LOINC | Name | R/O/C | Cardinality | Example UCUM Units |
---|---|---|---|---|
81959-9 | Public health laboratory ask at order entry panel | |||
Indent81744-5 | Submitter's laboratory test method [Type] in Specimen | |||
Indent81658-7 | Suspected organism [Identifier] in Specimen | |||
Indent86952-9 | Preliminary testing done Specimen | |||
Indent86953-7 | Preliminary testing result Specimen | |||
Indent86955-2 | Preliminary testing affected submission for further testing Specimen | |||
Indent95417-2 | Whether this is the patient's first test for condition of interest | |||
Indent95418-0 | Whether patient is employed in a healthcare setting | |||
Indent95419-8 | Whether the patient has symptoms related to condition of interest | |||
Indent11368-8 | Illness or injury onset date and time | C | ||
Indent77974-4 | Whether the patient was hospitalized for condition of interest | |||
Indent95420-6 | Whether the patient was admitted to intensive care unit (ICU) for condition of interest | |||
Indent95421-4 | Whether patient resides in a congregate care setting | |||
Indent82810-3 | Pregnancy status | C | ||
Indent30525-0 | Age | a |
Basic Attributes
- Class
- MICRO
- Type
- Laboratory
- First Released
- Version 2.68
- Last Updated
- Version 2.75
- Order vs. Observation
- Observation
Member of these Groups Get Info
LOINC Group | Group Name |
---|---|
LG51018-6 | SARSCoV2 antibody detection |
Language Variants Get Info
Tag | Language | Translation |
---|---|---|
de-DE | German (Germany) | SARS-Coronavirus 2 Ak.neutralisierend: Synonyms: pVNT |
es-ES | Spanish (Spain) | Panel del SARS-CoV-2 (COVID-19) Anticuerpos antineutrófilos: Synonyms: Semicuantitativo |
es-MX | Spanish (Mexico) | SARS coronavirus 2 Ab.neut: |
fr-FR | French (France) | Coronavirus SARS-CoV-2 Ac neutralisant: |
it-IT | Italian (Italy) | SARS coronavirus 2 Ab.Neut: Synonyms: anticorpo Coronavirus della SARS Microbiologia Punto nel tempo (episodio) SARS-CoV-2 (COVID-19) Siero Titolo |
nl-NL | Dutch (Netherlands) | SARS-CoV-2 As.neutraliserend: Synonyms: antistof; |
zh-CN | Chinese (China) | SARS 冠状病毒 2 抗体.中和: Synonyms: 2019 新型冠状病毒; |
Example Units
Unit | Source |
---|---|
{titer} | Example UCUM Units |
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=95410-7
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright